| Literature DB >> 34925157 |
Andreea Bogdana Isbăşoiu1, Bogdan Tudor Tulbure1, Andrei Rusu1, Florin Alin Sava1.
Abstract
Background: Internet-delivered psychotherapy represents an impactful large-scale solution for addressing psychological disorders. In spite of its flexibility and scalability, the fact that the ones in need have to initiate and sustain the curse of the treatment by themselves comes with considerable downsides in terms of treatment adherence. One solution could be to increase the ease of use and attractivity of the strategies and assignments from such programs. The present study aims to address this issue by incorporating a series of self-oriented strategies to the validated internet-delivered short version of the Unified Protocol (UP). By this mean we intend to complement the symptom-focused assignments, which may be more suitable in a therapist assisted context, with ones designed for self-enhancement, which may be easier approached as self-initiated. Based on a randomized controlled non-inferiority trial we compared the modified version of the UP with the standard short version. Method: The trial design was factorial, with two parallel arms and three measurement moments (baseline, post-intervention and 6-months follow-up). A total of 284 participants were randomly assigned to the intervention or the active control groups. The intervention group (baseline n = 142) received the self-enhanced nine modules of the UP (Self-enhanced 9UP) while the active control (baseline n = 142) received the standard nine modules (9UP). The newly added techniques were inspired by the acceptance and commitment therapy and were specific for self-concepts such as self-compassion or unconditional self-acceptance. Both programs lasted for 9 weeks. The non-inferiority of the Self-enhanced 9UP was tested against a margin of d = -0.35, on the following primary outcome measures: Patient Health Questionnaire 9 (PHQ9) - operationalization for depression; Generalized Anxiety Disorder 7 (GAD7) - operationalization for generalized anxiety or worry; Social Phobia Inventory (SPIN) - operationalization for social phobia; and Panic Disorder Severity Scale-Self Report (PDSS-SR) - that showed participants' level of panic. Treatment adherence was assessed through the drop-out analyses and the engagement in completing the homework assignments. Secondary outcome measures included several self-concept measures: Self-Compassion Scale (SCS); Rosenberg Self-Esteem Scale (RSES); Unconditional Self-Acceptance Questionnaire (USAQ); New General Self-Efficacy Scale (NGSE); and Self-Concept Clarity Scale (SCCS). On the secondary outcomes we explored the potential boost of effectiveness produced by the newly added self-enhancement components.Entities:
Keywords: anxiety; depression; non-inferiority trial; self-enhance; transdiagnostic; treatment adherence; unified protocol
Year: 2021 PMID: 34925157 PMCID: PMC8675898 DOI: 10.3389/fpsyg.2021.752249
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Overview of the newly added self-enhancement applications.
|
|
|
|
|
| 1 | Gratitude and ways to cultivate it | Grounds for gratitude – finding reasons for being grateful in everyday life. |
|
| 2 | Altruism and generosity towards others | Planning acts of generosity towards the others. |
|
| 3 | Self-compassion and how can we improve it (part 1) | Imagining your compassionate self – description of the experience in a pleasant and relaxing place. |
|
| 4 | Self-compassion and how can we improve it (part 2) | A letter of self-compassion – for the validation of the compassionate self. |
|
| 5 | Unconditional self-acceptance and how can we improve it (part 1) | Diffusion practices for everyday life – a journal of behaviors based on unconditional acceptance and goodwill. |
|
| 6 | Unconditional self-acceptance and how can we improve it (part 2) | Breaking identification with thoughts – keeping a diary of the daily “monsters.” |
|
| 7 | Self-esteem and how can we improve it (part 1) | Journal of unrealistic and exaggerated expectations. |
|
| 8 | Self-esteem and how can we improve it (part 2) | Identifying the ineffective rules and assumptions. |
|
| 9 | Life after treatment. Recognition of achievements and future plans | Putting events in perspective: what could I still do? |
|
FIGURE 1The flowchart displaying participants’ cycle throughout the study.
Baseline characteristics of the participants in the two groups and the entire sample.
|
|
|
|
|
|
|
| Age (years) | 0.81 | ||||
| Mean ( | 33.34(10.20) | 33.06 (10.02) | 33.20 (10.09) | ||
| Gender, | χ2 = 0.43 (1) | 0.51 | |||
| Male | 24 (16.9) | 20 (14.1) | 44 (15.5) | ||
| Female | 118 (83.1) | 122 (85.9) | 240 (84.5) | ||
| Educational level, | χ2 = 0.94 (1) | 0.53 | |||
| Higher education | 103 (72.53) | 105 (73.94) | 208 (73.24) | ||
| High school or lower | 39 (27.47) | 37 (26.06) | 76 (26.76) | ||
| Marital status, | χ2 = 5.02 (4) | 0.28 | |||
| Never married | 56 (39.43) | 49 (34.5) | 105 (36.97) | ||
| In a relationship | 29 (20.42) | 24 (16.9) | 53 (18.66) | ||
| Married | 40 (28.16) | 54 (38.02) | 94 (33.09) | ||
| Divorced | 15 (10.56) | 15 (10.56) | 30 (10.56) | ||
| Widowed | 2 (1.4) | 0 (0.0) | 2 (0.7) | ||
| Primary diagnostic, | χ2 = 10.94 (9) | 0.28 | |||
| GAD | 21 (14.78) | 322(2.53) | 53 (18.66) | ||
| SAD | 8 (5.63) | 8 (5.63) | 16 (5.63) | ||
| MDD | 41 (28.87) | 38 (26.76) | 79 (27.81) | ||
| PD/A | 26(18.3) | 18(12.67) | 44 (15.49) | ||
| PDD | 42(29.57) | 43(30.28) | 85 (29.92) | ||
| Other | 4 (2.81) | 3 (2.11) | 7 (2.46) | ||
| Secondary diagnostic, | χ2 = 20.68(17) | 0.24 | |||
| GAD | 46 (32.39) | 38 (26.76) | 84 (29.57) | ||
| SAD | 9 (6.33) | 23 (16.19) | 32 (11.26) | ||
| MDD | 7 (4.92) | 14 (9.85) | 21 (7.39) | ||
| PD/A | 28 (19.71) | 24 (16.9) | 52 (18.3) | ||
| SP | 1 (0.7) | 1 (0.7) | 2 (0.7) | ||
| PDD | 24 (16.9) | 17 (11.97) | 41 (14.43) | ||
| Other | 15 (10.56) | 14 (9.85) | 29 (10.21) | ||
| Comorbid diagnostic, | χ2 = 55.71(19) | 0.49 | |||
| GAD | 23 (16.19) | 21 (14.78) | 44 (15.49) | ||
| SAD | 12 (8.45) | 12 (8.45) | 24 (8.45) | ||
| MDD | 8 (5.63) | 8 (5.63) | 16 (5.63) | ||
| PD/A | 9 (6.33) | 8 (5.63) | 17 (5.98) | ||
| PDD | 9 (6.33) | 7 (4.92) | 16 (5.63) | ||
| Other | 8 (5.63) | 12 (8.45) | 20 (7.04) | ||
| Previous psychotherapy (in the last 4 years), | χ2 = 0.14 (1) | 0.70 | |||
| Yes | 47 (33.09) | 44 (30.98) | 91 (32.04) | ||
| No | 95 (66.9) | 98 (69.01) | 193 (67.95) | ||
| Previous psychiatric diagnostic, | χ2 = 0.15 (1) | 0.69 | |||
| Yes | 40 (28.16) | 43 (30.28) | 83 (29.22) | ||
| No | 102 (71.83) | 99 (69.71) | 201 (70.77) | ||
| Currently under medication, | χ2 = 0.94 (1) | 0.33 | |||
| Yes | 15 (10.56) | 20 (14.08) | 35 (12.32) | ||
| No | 127 (89.43) | 122 (85.91) | 249 (87.67) | ||
| Time spent online (hours/day) | 0.24 | ||||
| Mean ( | 4.67 (3.21) | 4.26 (2.71) | 4.46 (2.69) | ||
| Treatment credibility | |||||
| Mean ( | 38.91 (7.79) | 39.19 (7.52) | 39.05 (7.65) | 0.77 | |
GAD, generalized anxiety disorder; SAD, social anxiety disorder; MDD, major depressive disorder; PD/A, panic disorder/agoraphobia; PTSD, post-traumatic stress disorder; OCD, obsessive compulsive disorder; PDD, persistent depressive disorder.
Estimated differences in mean change between baseline and post intervention, respectively, follow-up, for the intervention versus the control group (group by time interactions).
|
|
|
|
|
|
|
| ||||
| PHQ9 | Post-intervention | 0.47 [–1.37, 2.31] | 0.50 (418) | –0.04 [–0.18, 0.11] |
| Follow-up | 1.45 [–1.27, 4.17] | 1.05 (338) | –0.10 [–0.29, 0.09] | |
| GAD7 | Post-intervention | 1.26 [–0.47, 2.99] | 1.43 (415) | –0.10 [–0.24, 0.04] |
| Follow-up | 0.51 [–1.80, 2.83] | 0.43 (336) | –0.04 [–0.21, 0.14] | |
| SPIN | Post-intervention | 2.96 [–0.91, 6.83] | 1.50 (421) | –0.11 [–0.26, 0.03] |
| Follow-up | 3.80 [–1.67, 9.28] | 1.36 (343) | –0.13 [–0.32, 0.06] | |
| PDSS-SR | Post-intervention | 1.30 [–0.20, 2.80] | 1.70 (417) | –0.13 [–0.28, 0.02] |
| Follow-up | 0.76 [1.69, 3.22] | 0.61 (338) | –0.06 [–0.27, 0.14] | |
|
| ||||
| SCCS | Post-intervention | –1.13 [–4.30, 2.04] | −2.70(414) | –0.05 [–0.09, –0.19] |
| Follow-up | –1.29 [–5.36, 2.78] | −0.62(336) | 0.06 [–0.13, 0.26] | |
| NGSE | Post-intervention | –1.59 [–3.88, 0.69] | −1.37(414) | 0.10 [–0.05, 0.25] |
| Follow-up | –0.09 [–3.42, 3.24] | −0.05(334) | 0.01 [–0.20, 0.21] | |
| USAQ | Post-intervention | 0.75 [4.18, 5.68] | 0.30 (414) | –0.02 [0.17, –0.12] |
| Follow-up | –3.09 [–10.34, 4.16] | −0.83(333) | 0.08 [–0.11, 0.28] | |
| RSES | Post-intervention | –1.10 [–2.66, 0.46] | −1.38(418) | 0.10 [–0.04, –0.25] |
| Follow-up | –1.41 [–3.62, 0.79] | −1.26(336) | 0.13 [–0.08, 0.34] | |
| SCS | Post-intervention | –1.73 [–8.05, 4.58] | −0.54(414) | 0.04 [0.10, –0.17] |
| Follow-up | –1.36 [–9.63, 6.90] | −0.32(333) | 0.03 [–0.14, 0.19] | |
*All
b, Mean change difference in treatment versus control group estimate; d, Cohen’s
Estimates of mean differences between baseline and post intervention, respectively, follow-up (within-group effects).
|
|
|
|
| ||||
|
|
|
|
|
|
| ||
|
| |||||||
| PHQ9 | Post-intervention | –6.31 [–7.52, –5.10] | −10.23(243) | 0.74 [0.55, 0.93] | –5.89 [–7.23, –4.56] | −8.66(238) | 0.93 [0.71, 1.14] |
| Follow-up | –7.75 [–9.36, –6.13] | −9.41(243) | 0.56 [0.38, 0.74] | –6.34 [–8.21, –4.48] | −6.68(238) | 0.84 [0.64, 1.04] | |
| GAD7 | Post-intervention | –6.09 [–7.27, –4.90] | −10.08(240) | 0.72 [0.91, 0.53] | –4.78 [–5.91, –3.64] | −8.26(237) | 0.86 [0.67, 1.06] |
| Follow-up | –6.23 [–7.81, –4.65] | −7.74(240) | 0.56 [0.37, 0.74] | –5.25 [–6.83, –3.66] | −6.50(237) | 0.65 [0.47, 0.83] | |
| SPIN | Post-intervention | –11.31 [–13.68, –8.94] | −9.34(245) | 0.49 [0.31, 0.68] | –8.17 [–11.02, –5.32] | −5.62(243) | 0.83 [0.63, 1.03] |
| Follow-up | –14.88 [–17.99, –11.78] | −9.40(245) | 0.46 [0.28, 0.64] | –10.68 [–14.61, –6.75] | −5.33(243) | 0.83 [0.63, 1.03] | |
| PDSS-SR | Post-intervention | –3.53 [–4.60, –2.46] | −6.47(243) | 0.40 [0.21, 0.58] | –2.24 [–3.25, –1.22] | −4.33(238) | 0.60 [0.40, 0.79] |
| Follow-up | –4.31 [–5.71, –2.90] | −5.99(243) | 0.45 [0.26, 0.64] | –3.57 [–4.99, –2.15] | −4.92(238) | 0.55 [0.36, 0.74] | |
|
| |||||||
| SCCS | Post-intervention | 8.01 [6.08, 9.93] | 8.16 (239) | 0.50 [0.31, 0.68] | 6.83 [4.48, 9.19] | 5.68 (237) | 0.72 [0.52, 0.91] |
| Follow-up | 10.45 [7.89, 13.01] | 8.00 (239) | 0.47 [0.29, 0.65] | 9.23 [5.93, 12.52] | 5.49 (237) | 0.70 [0.51, 0.89] | |
| NGSE | Post-intervention | 6.51 [4.82, 8.20] | 7.56 (238) | 0.60 [0.40, 0.79] | 4.87 [3.42, 6.33] | 6.56 (236) | 0.68 [0.48, 0.88] |
| Follow-up | 5.22 [2.96, 7.48] | 4.53 (238) | 0.44 [0.25, 0.62] | 5.03 [2.97, 7.10] | 4.78 (236) | 0.39 [0.22, 0.57] | |
| USAQ | Post-intervention | 13.84 [10.42, 17.26] | 7.93 (238) | 0.74 [0.54, 0.94] | 14.60 [11.16, 18.04] | 8.32 (232) | 0.71 [0.52, 0.91] |
| Follow-up | 17.30 [12.67, 21.93] | 7.32 (238) | 0.50 [0.31, 0.68] | 14.57 [9.50, 19.64] | 5.63 (232) | 0.65 [0.46, 0.85] | |
| RSES | Post-intervention | 5.08 [4.01, 6.15] | 9.32 (238) | 0.67 [0.47, 0.87] | 4.02 [2.95, 5.08] | 7.39 (236) | 0.84 [0.63, 1.05] |
| Follow-up | 5.87 [4.42, 7.32] | 7.94 (238) | 0.52 [0.33, 0.71] | 4.68 [3.10, 6.25] | 5.82 (236) | 0.71 [0.52, 0.91] | |
| SCS | Post-intervention | 19.67 [15.52, 23.82] | 9.30 (238) | 0.70 [0.51, 0.88] | 18.14 [13.83, 22.45] | 8.25 (235) | 0.80 [0.60, 0.99] |
| Follow-up | 20.65 [15.08, 26.22] | 7.27 (238) | 0.52 [0.35, 0.69] | 20.03 [13.85, 26.21] | 6.36 (235) | 0.61 [0.43, 0.79] | |
*All
d, Cohen’s
Between-groups t-test comparisons for non-inferiority on all primary outcomes against the non-inferiority margin of d = –0.35.
|
|
|
|
|
|
|
| ||||
| PHQ9 | Post-intervention | 1.86 (89) | 0.033 | [–0.37,0.45] |
| Follow-up | 1.96 (46) | 0.028 | [–0.35,0.78] | |
| GAD7 | Post-intervention | 3.26 (89) | <0.001 | [–0.08,0.75] |
| Follow-up | 1.79 (46) | 0.040 | [–0.40,0.73] | |
| SPIN | Post-intervention | 3.43 (90) | <0.001 | [–0.05,0.77] |
| Follow-up | 2.46 (48) | 0.009 | [–0.22,0.90] | |
| PDSS-SR | Post-intervention | 2.85 (88) | 0.003 | [–0.16,0.66] |
| Follow-up | 1.28 (47) | 0.103 | [–0.55,0.58] | |
|
| ||||
| PHQ9 | Post-intervention | 2.79 (275) | 0.003 | [–0.25,0.22] |
| Follow-up | 3.31 (275) | <0.001 | [–0.19,0.28] | |
| GAD7 | Post-intervention | 3.74 (274) | <0.001 | [–0.11,0.37] |
| Follow-up | 3.98 (274) | <0.001 | [–0.11,0.37] | |
| SPIN | Post-intervention | 4.05 (276) | <0.001 | [–0.10,0.37] |
| Follow-up | 4.43 (276) | <0.001 | [–0.05,0.42] | |
| PDSS-SR | Post-intervention | 4.13 (274) | <0.001 | [–0.09,0.38] |
| Follow-up | 3.98 (274) | <0.001 | [–0.11,0.37] | |
|
| ||||
| PHQ9 | Post-intervention | 1.87 (146) | 0.032 | [–0.37,0.28] |
| Follow-up | 2.88 (67) | <0.001 | [–0.13,0.82] | |
| GAD7 | Post-intervention | 3.16 (144) | <0.001 | [–0.15,0.49] |
| Follow-up | 1.97 (66) | 0.027 | [–0.35,0.60] | |
| SPIN | Post-intervention | 3.42 (148) | <0.001 | [–0.11,0.53] |
| Follow-up | 2.95 (71) | 0.002 | [–0.12,0.80] | |
| PDSS-SR | Post-intervention | 3.39 (145) | <0.001 | [–0.12,0.53] |
| Follow-up | 1.77 (68) | 0.041 | [–0.39,0.55] |
*Reference
Descriptive statistics for the treatment satisfaction items.
|
|
|
|
|
|
|
| 1 | Overall, how satisfied are you with the treatment you received? ( | 4.35 (0.75) | 4.40 (0.70) | −0.42(139) | 0.67 |
| 2 | How would you evaluate the quality of the information that was provided? ( | 4.60 (0.92) | 4.52 (0.97) | 0.53 (139) | 0.59 |
| 3 | How satisfied were you with the timing of the treatment program? ( | 2.54 (0.83) | 2.58 (0.84) | −0.29(139) | 0.76 |
| 4 | How many modules did you fully understood? ( | 7.01 (1.88) | 7.16 (1.88) | −0.47(139) | 0.63 |
| 5 | Please, estimate the average number of hours you spent in a week on the program. | 4.79 (4.29) | 4.95 (4.98) | −0.20(133) | 0.83 |
| 6 | How demanding were the activities? ( | 2.78 (0.65) | 2.77 (0.75) | 0.06 (139) | 0.94 |
| 7 | The program helped me approach my problems more effectively. ( | 3.47 (0.55) | 3.38 (0.63) | 0.85 (139) | 0.39 |
| 8 | How logical seemed to you the method that we used? ( | 8.25 (1.89) | 8.08 (2.07) | 0.50 (139) | 0.61 |
| 9 | How confident would you be to recommend this method of treatment? ( | 8.52 (1.77) | 7.94 (2.67) | 1.52 (113) | 0.13 |